Many people encounter vasoactive intestinal peptide (VIP) in the context of clinical research rather than everyday medicine, and the available label data here is limited. This overview focuses on what can be confirmed from registered trials and chemical identity rather than approved-use claims, since no indications or mechanism text was provided.
Key takeaways
- Vasoactive intestinal peptide is a large peptide compound with the molecular formula C147H237N43O43S.
- It has a molecular weight of approximately 3,326.8 g/mol, reflecting its complex, multi-amino-acid structure.
- At least 60 clinical trials have been registered that involve this compound.
- Sample trials span varied settings, including herpes zoster biomarker research, oncology, and post-surgical recovery studies.
- No FDA label indications, mechanism, or side effect reporting data were available for this summary.
What vasoactive intestinal peptide is
Vasoactive intestinal peptide is a peptide compound identified in chemical databases under PubChem CID 53314964. It is composed of a long chain of amino acids, giving it a molecular weight far larger than typical small-molecule drugs. No FDA-approved label, indications, or mechanism of action description was available in the data reviewed for this article.
What the evidence shows
At least 60 clinical trials referencing this compound have been registered. Sample studies illustrate the breadth of research interest rather than a single focused use. One completed trial examined biomarkers in patients with herpes zoster (NCT05685797), while another, now not yet recruiting, is exploring recovery timing after gastrectomy (NCT07714980). A separate early-phase oncology trial involving locally advanced or metastatic solid tumors was terminated (NCT00112684).